10 Years Of MedImmune: How License Agreements Changed

Law360, New York (February 15, 2017, 11:50 AM EST) -- Last month marked 10 years since the U.S. Supreme Court sided with MedImmune in a royalty dispute with Genentech, transferring the power within a license agreement from the licensor to the licensee. This Law360 Expert Analysis series explores the decision's impact on licensing and litigation.

Jonathan Lourie

Vicki G. Norton A decade ago, the U.S. Supreme Court’s ruling in MedImmune LLC v. Genentech Inc.[1] permitted patent licensees to seek declaratory judgments of patent invalidity, unenforceability or noninfringement without first terminating or breaching the license agreement. Prior to MedImmune,...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.